Skip to Content
Merck

Percutaneous bone lesion ablation.

La Radiologia medica (2014-06-05)
Dimitrios K Filippiadis, Sean Tutton, Alexis Kelekis
ABSTRACT

Benign tumors and metastatic bone lesions can be treated by ablation techniques performed either alone or in combination with other percutaneous techniques. Ablation techniques include ethanol or acetic acid injection and thermal ablation by means of energy deposition [including laser, radiofrequency, microwave, cryoablation, radiofrequency ionization and magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU)]. Goal definition of the therapy is crucial: ablation techniques can be proposed as curative treatments in benign bone tumors or oligometastatic disease (<3 lesions). Alternatively, these techniques can be proposed as palliative treatments aiming at reduction of pain, local control of the disease and tumor decompression. Depending on the lesion's location ablation can be combined with cementation with or without further metallic augmentation; local tumor control can be enhanced by combining ablation with transarterial bland embolization or chemoembolization. Thermal ablation of bone and soft tissues is characterized by high success and relatively low rates of potential complications, mainly iatrogenic thermal damage of surrounding sensitive structures. Successful thermal ablation requires a sufficient ablation volume and thermal protection of the surrounding vulnerable structures. This article will describe the general principles governing ablation and the mechanism of action for each technique and in addition will review the literature about safety and effectiveness of percutaneous imaging-guided ablation for benign and malignant (primary and metastatic) lesions.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acetic acid, natural, ≥99.5%, FG
Sigma-Aldrich
Acetic acid, ≥99.5%, FCC, FG
Supelco
Acetic acid, analytical standard
Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Sigma-Aldrich
Reagent Alcohol, anhydrous, ≤0.003% water
Sigma-Aldrich
Acetic acid, for luminescence, BioUltra, ≥99.5% (GC)
Supelco
Ethanol-500, 500 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
USP
Dehydrated Alcohol, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Acetic acid, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
Acetic acid, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
Acetic acid solution, suitable for HPLC
Sigma-Aldrich
Acetic acid, glacial, ReagentPlus®, ≥99%
Supelco
Ethanol-150, 150 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Millipore
Bifido Selective Supplement B, suitable for microbiology
Supelco
Ethanol-80, 80 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Supelco
Ethanol-100 (10 ampules/kit), 100 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Supelco
Ethanol-200 (10 ampules/kit), 200 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Supelco
Ethanol-300, 300 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, ACS reagent, ≥99.5%
Supelco
Ethanol-50, 50 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
USP
Glacial acetic acid, United States Pharmacopeia (USP) Reference Standard